AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30021566 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acceptance based psychosocial HIV prevention intervention (four group and six individual counseling sessions, including standard of care HIV/STI testing and counseling)
Number of subjects: 0
Study 30021566 — intervention group
Group type: COMPARATOR
Intervention: Standard of care condition (HIV/STI testing and counseling alone)
Number of subjects: 0
Study 27351719 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 17
Study 24445534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG +); n=151 patients
Number of subjects: 600
Study 24445534 — intervention group
Group type: COMPARATOR
Intervention: No self-monitoring of blood glucose (SMBG -); n=149 patients
Number of subjects: 600
Study 24445534 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HbA(1c) results (HbA(1c) +); n=158 patients
Number of subjects: 600
Study 24445534 — intervention group
Group type: COMPARATOR
Intervention: No disclosure of HbA(1c) results (HbA(1c) -); n=142 patients
Number of subjects: 600
Study 22734013 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 245
Study 22734013 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis alone (Control)
Number of subjects: 245
Study 19766403 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD+MDD
Number of subjects: 34
Study 19766403 — intervention group
Group type: COMPARATOR
Intervention: PTSD-MDD
Number of subjects: 34
Study 19766403 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 19766403 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 34
Study 16963171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (AD, Admira/Admira Bond, VOCO)
Number of subjects: 32
Study 16963171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (DE, Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32
Study 16963171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis-GMA-based composite (TC, Tetric-Ceram/Syntac, Ivoclar-Vivadent)
Number of subjects: 32
Study 16963171 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups (AD, DE, TC)
Number of subjects: 32
Study 16963171 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface roughness (AD and TC)
Number of subjects: 32
Study 16963171 — intervention group
Group type: COMPARATOR
Intervention: Restoration size (> or = 3 surfaces)
Number of subjects: 32
Study 16262965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 16262965 — intervention group
Group type: COMPARATOR
Intervention: No intervention (without HRT)
Number of subjects: 0
Study 12015517 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Number of subjects: 831
Study 12015517 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment (intravenous cefoxitin and doxycycline)
Number of subjects: 831
Study 12015517 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 831
Study 12015517 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 831
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon with isoflurane
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon with sevoflurane
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O with isoflurane
Number of subjects: 162
Study 11046204 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O with sevoflurane
Number of subjects: 162
Study 9346384 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment (group II, n = 42)
Number of subjects: 108
Study 9346384 — intervention group
Group type: COMPARATOR
Intervention: Untreated anemic controls (group I, n = 31)
Number of subjects: 108
Study 9346384 — intervention group
Group type: COMPARATOR
Intervention: Untreated nonanemic controls (group III, n = 35)
Number of subjects: 108
Study 1443808 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 bolus, continuous infusion of 5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Number of subjects: 30
Study 1443808 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.3 mg.kg‐1 bolus, continuous infusion of 1.5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Number of subjects: 30
Study 3989142 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-modified ragweed extract (10 weekly injections for group 1, 6 injections for group 2, followed by 10 injections before the second season)
Number of subjects: 62
Study 3989142 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-modified ragweed extract
Number of subjects: 62
Study 3989142 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study 28891228 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 35
Study 28891228 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 35
Study 27182022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcoming Compassion Fatigue Program (5 weekly 80-minute sessions)
Number of subjects: 32
Study 27182022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 32
Study 24236767 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular presentation of images to the same or different eyes
Number of subjects: 0
Study 24236767 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular presentation of images
Number of subjects: 0
Study 24236767 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular mechanisms
Number of subjects: 0
Study 22515588 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy alone (Group 1)
Number of subjects: 30
Study 22515588 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy with psoralen gel (Group 2)
Number of subjects: 30
Study 22515588 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy with calcipotriol ointment (Group 3)
Number of subjects: 30
Study 20447203 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 24
Study 20447203 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 24
Study 18805053 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring analysis
Number of subjects: 620
Study 18805053 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 620
Study 15959784 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight hyaluronan (hylan G-F 20)
Number of subjects: 59
Study 15959784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower molecular weight hyaluronan
Number of subjects: 59
Study 15959784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 59
Study 15959784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15959784 — intervention group
Group type: COMPARATOR
Intervention: All groups (HA and placebo)
Number of subjects: 59
Study 12676890 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1 mg)
Number of subjects: 8
Study 12676890 — intervention group
Group type: COMPARATOR
Intervention: d-Amphetamine (0, 2.5, 5, 10, and 15 mg)
Number of subjects: 8
Study 12676890 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0 mg)
Number of subjects: 8
Study 11147984 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based primary care (n=981)
Number of subjects: 1966
Study 11147984 — intervention group
Group type: COMPARATOR
Intervention: Customary VA and private sector care (n=985)
Number of subjects: 1966
Study 8871795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (16 individual sessions over 4 months)
Number of subjects: 32
Study 8871795 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (no treatment for 4 months)
Number of subjects: 32
Study 1499947 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (50 ng.kg‐1.min‐1)
Number of subjects: 16
Study 1499947 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (5 mg/2 min followed by 500 micrograms/min)
Number of subjects: 16
Study 1499947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (5 mg/2 min followed by 80 micrograms/min)
Number of subjects: 16
Study 1499947 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 29203153 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound unilateral subthalamotomy
Number of subjects: 10
Study 27683840 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAP 10 cmH2O
Number of subjects: 24
Study 27683840 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAP 15 cmH2O
Number of subjects: 24
Study 25025852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghavoot (34 g/dl) dissolved in 400 ml milk
Number of subjects: 22
Study 25025852 — intervention group
Group type: COMPARATOR
Intervention: Control group received 400 ml milk
Number of subjects: 22
Study 22075751 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg/d for 3 weeks
Number of subjects: 864
Study 20561856 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation (MHI)
Number of subjects: 30
Study 20561856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation (VHI)
Number of subjects: 30
Study 17716936 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC
Number of subjects: 1780
Study 17716936 — intervention group
Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib
Number of subjects: 1780
Study 15980845 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional drainage
Number of subjects: 112
Study 15980845 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening of the pulp chamber drainage
Number of subjects: 112
Study 15980845 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 112
Study 15980845 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-resistant bacteria presence
Number of subjects: 112
Study 12897561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol 5 to 8 mg.kg‐1.h‐1 and remifentanil 10 to 30 microg.kg‐1.h‐1
Number of subjects: 90
Study 12897561 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.4‐1.0 vol%) and repetitive doses of 0.5 to 1 mg alfentanil
Number of subjects: 90
Study 12897561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol-remifentanil
Number of subjects: 90
Study 12897561 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia with isoflurane-alfentanil
Number of subjects: 90
Study 10581665 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency treatment for acute exacerbations of obstructive pulmonary disease
Number of subjects: 50
Study 8721800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention based on NCEP-ATP I fat-modified step I diet specifications, consisting of five sessions over an 8-week period.
Number of subjects: 77
Study 8721800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postintervention nutrition data for 20 screenees randomized into the study.
Number of subjects: 77
Study 1667469 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice (1.3% soluble pyrophosphate and 1.5% Gantrez copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 0
Study 1667469 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 0
Study 6858922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study 30729554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Number of subjects: 22
Study 30729554 — intervention group
Group type: COMPARATOR
Intervention: Regular Dental Environment (RDE)
Number of subjects: 22
Study 29206719 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic procedures for mixed and other types of UI
Number of subjects: 1000000
Study 29206719 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures for urge or stress UI
Number of subjects: 1000000
Study 29206719 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization in patients with UI
Number of subjects: 1000000
Study 26511068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8246
Study 26511068 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKAs
Number of subjects: 8246
Study 25145986 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite sublingual immunotherapy (SLIT) with Dermatophagoides farinae extracts for 52 weeks, combined with standard pharmacotherapy.
Number of subjects: 112
Study 22233697 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone oral solution (RIS-OS) plus clonazepam
Number of subjects: 205
Study 22233697 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 205
Study 22233697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (RIS-OS plus clonazepam)
Number of subjects: 205
Study 22233697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments after 6-week treatment
Number of subjects: 205
Study 20059420 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival air polishing with a new device
Number of subjects: 50
Study 20059420 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 50
Study 17077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 0
Study 17077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY
Number of subjects: 0
Study 17077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide
Number of subjects: 0
Study 17077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1
Number of subjects: 0
Study 17077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Number of subjects: 0
Study 14613759 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin (400mg/capsule/day) for 8 weeks
Number of subjects: 30
Study 10753245 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (7 microg/kg/d when fed parenterally and 5 microg/kg/d when fed orally)
Number of subjects: 534
Study 10753245 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 534
Study 10753245 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 534
Study 8602586 — intervention group
Group type: COMPARATOR
Intervention: BPVEM diet
Number of subjects: 14
Study 8602586 — intervention group
Group type: EXPERIMENTAL
Intervention: LWF diet
Number of subjects: 14
Study 1413608 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted sulfur mud baths
Number of subjects: 16
Study 1413608 — intervention group
Group type: COMPARATOR
Intervention: Diluted mud baths without sulfur compounds
Number of subjects: 16
Study 3880641 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Healonid injected into the anterior chamber
Number of subjects: 27
Study 3880641 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone
Number of subjects: 27
Study 31793231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rezafungin (600 mg and 1400 mg)
Number of subjects: 0
Study 31793231 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 0
Study 31793231 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study 30616912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (NEMO-500MG)
Number of subjects: 995
Study 30616912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg (NEMO-750MG)
Number of subjects: 995
Study 30616912 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg (LEVO)
Number of subjects: 995
Study 27845338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐CBT (10-week intervention focused on exposure to IBS symptoms)
Number of subjects: 101
Study 27845338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐CBT
Number of subjects: 101
Study 27845338 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101
Study 25813563 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation
Number of subjects: 28
Study 25813563 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 28
Study 23276821 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel/sorafenib
Number of subjects: 22
Study 23276821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21329501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST) delivered to participants with mild AD and their companions together.
Number of subjects: 128
Study 21329501 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST) delivered to companions of participants with mild AD alone.
Number of subjects: 128
Study 21329501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST) for participants with mild AD and their companions together.
Number of subjects: 128
Study 21329501 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST) for companions of participants with mild AD alone.
Number of subjects: 128
Study 20110015 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic chlorphenesin carbamate 250 mg
Number of subjects: 28
Study 20110015 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic chlorphenesin carbamate 500 mg
Number of subjects: 28
Study 20110015 — intervention group
Group type: COMPARATOR
Intervention: Branded chlorphenesin carbamate 250 mg
Number of subjects: 28
Study 20110015 — intervention group
Group type: COMPARATOR
Intervention: Branded chlorphenesin carbamate 500 mg
Number of subjects: 28
Study 20110015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (generic and branded)
Number of subjects: 28
Study 17286150 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm 1,4-dioxane vapour for 2 hours
Number of subjects: 12
Study 17286150 — intervention group
Group type: COMPARATOR
Intervention: Control exposure (0 ppm 1,4-dioxane vapour) for 2 hours
Number of subjects: 12
Study 15385380 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with lidocaine 1.5% 15 mL (group FEM)
Number of subjects: 20
Study 15385380 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl 3 microg/kg (group IVA)
Number of subjects: 20
Study 11118395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route
Number of subjects: 141
Study 11118395 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous route
Number of subjects: 141
Study 9701523 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole therapy (duration: 80 months for hypergastrinaemia group, 55 months for control group)
Number of subjects: 26
Study 9701523 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole therapy
Number of subjects: 26
Study 8254816 — intervention group
Group type: EXPERIMENTAL
Intervention: RDA multivitamins plus 40,000 units vitamin A, 100 mg. vitamin B6, 2,000 mg. vitamin C, 400 units vitamin E and 90 mg. zinc
Number of subjects: 65
Study 8254816 — intervention group
Group type: COMPARATOR
Intervention: RDA multivitamins
Number of subjects: 65
Study 2572666 — intervention group
Group type: COMPARATOR
Intervention: xamoterol 200 mg b.i.d. for 4 weeks
Number of subjects: 28
Study 1058527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days pretreatment with 1‐asparaginase and prednisolone followed by a combination of rubidomycin and cytosine arabinoside (ARAP)
Number of subjects: 77
Study 1058527 — intervention group
Group type: COMPARATOR
Intervention: Treatment with a combination of rubidomycin, cytosine arabinoside and prednisolone without 1‐asparaginase pretreatment (RAP)
Number of subjects: 77
Study 31130504 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 52
Study 31130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone 0.1% cream
Number of subjects: 52
Study 28262319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone or budesonide) prescribed during ED visit for 1 month in addition to standard asthma therapy.
Number of subjects: 147
Study 28262319 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma therapy without inhaled corticosteroid prescription.
Number of subjects: 147
Study 26059225 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 16
Study 26059225 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg
Number of subjects: 16
Study 26059225 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 μg
Number of subjects: 16
Study 26059225 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 50/25-200/25 μg
Number of subjects: 16
Study 26059225 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI
Number of subjects: 16
Study 26059225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24228710 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 μg twice a day for 2 weeks
Number of subjects: 26
Study 21624699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 200
Study 21624699 — intervention group
Group type: COMPARATOR
Intervention: Simple emollient
Number of subjects: 200
Study 18774180 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 1051
Study 18774180 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 1051
Study 18774180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1051